Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.

Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.

PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24.

2.

Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations.

Neumann M, Heesch S, Gökbuget N, Schwartz S, Schlee C, Benlasfer O, Farhadi-Sartangi N, Thibaut J, Burmeister T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.

Blood Cancer J. 2012 Jan;2(1):e55. doi: 10.1038/bcj.2011.49. Epub 2012 Jan 27.

3.

Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.

Noronha EP, Andrade FG, Zampier C, de Andrade CF, Terra-Granado E, Pombo-de-Oliveira MS; Brazilian Study Group for Childhood Leukaemia.

Blood Cells Mol Dis. 2016 Mar;57:74-80. doi: 10.1016/j.bcmd.2015.12.003. Epub 2015 Dec 2.

PMID:
26852660
4.

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.

Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD.

Blood. 2013 Jun 6;121(23):4749-52. doi: 10.1182/blood-2012-11-465138. Epub 2013 Apr 19.

5.

Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.

Zaremba CM, Oliver D, Cavalier M, Fuda F, Karandikar NJ, Chen W.

Ann Diagn Pathol. 2012 Jan;16(1):16-20. doi: 10.1016/j.anndiagpath.2011.07.005. Epub 2011 Nov 3.

PMID:
22050963
6.

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?

Kawashima-Goto S, Imamura T, Tomoyasu C, Yano M, Yoshida H, Fujiki A, Tamura S, Osone S, Ishida H, Morimoto A, Kuroda H, Hosoi H.

PLoS One. 2015 Jul 14;10(7):e0132926. doi: 10.1371/journal.pone.0132926. eCollection 2015.

7.

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.

Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.

PMID:
27778197
8.

CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.

Hoehn D, Medeiros LJ, Chen SS, Tian T, Jorgensen JL, Ahmed Y, Lin P.

Am J Clin Pathol. 2012 Feb;137(2):213-9. doi: 10.1309/AJCPR3N3JMSYLPFG.

PMID:
22261446
9.

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE.

Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.

10.

Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.

Lhermitte L, Ben Abdelali R, Villarèse P, Bedjaoui N, Guillemot V, Trinquand A, Libura M, Bedin AS, Petit A, Dombret H, Leverger G, Ifrah N, Hermine O, Macintyre E, Asnafi V.

Leukemia. 2013 Feb;27(2):305-14. doi: 10.1038/leu.2012.177. Epub 2012 Jul 3.

PMID:
22751451
11.

Targeting FLT3 to treat leukemia.

Konig H, Levis M.

Expert Opin Ther Targets. 2015 Jan;19(1):37-54. doi: 10.1517/14728222.2014.960843. Epub 2014 Sep 18. Review.

12.

BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.

Kraszewska MD, Dawidowska M, Kosmalska M, Sędek L, Grzeszczak W, Kowalczyk JR, Szczepański T, Witt M; Polish Pediatric Leukemia Lymphoma Study Group (PPLLSG).

Blood Cells Mol Dis. 2013 Jan;50(1):33-8. doi: 10.1016/j.bcmd.2012.09.001. Epub 2012 Oct 3. Erratum in: Blood Cells Mol Dis. 2013 Jun;51(1):66-8.

PMID:
23040356
13.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

14.

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S, Mossner M, Schwartz S, Mochmann LH, Isaakidis K, Bastian L, Kees UR, Herold T, Spiekermann K, Gökbuget N, Baldus CD.

J Hematol Oncol. 2016 Sep 22;9(1):95.

15.

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.

Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19.

PMID:
26891877
16.
17.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

18.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

19.

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia.

Ma M, Wang X, Tang J, Xue H, Chen J, Pan C, Jiang H, Shen S.

Front Med. 2012 Dec;6(4):416-20. doi: 10.1007/s11684-012-0224-4. Epub 2012 Oct 12.

PMID:
23065427
20.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792

Supplemental Content

Support Center